Skip to main content
Caplight Logo









Oligomerix, Inc.

Oligomerix, Inc.

Private
Bronx, New YorkHealthcare & Life Scienceshttps://oligomerix.com/

Last Round

Grant

Nov 18, 2023

Total Funding Raised

$14.64M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Oligomerix, Inc. is a clinical-stage biotechnology company that develops oral, small molecule therapeutics for neurodegenerative diseases such as Alzheimer's by targeting the aggregation of the tau protein.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

tau inhibitorsmall molecule drugneurodegenerative diseasesoral therapeuticsAlzheimer's diseasetauopathiesdisease-modifying therapyclinical stage biotechprogressive supranuclear palsyPSPfrontotemporal dementiaFTDblood-brain barriercompanion biomarker

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oligomerix, Inc. Comparables

Compare Oligomerix, Inc. with similar companies based on industry and business-model similarity.

Oligomerix, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Treventis Corporation
86%
Asceneuron
84%
Alzprotect
81%

Oligomerix, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 18, 2023
GrantAug 9, 2022
Series B ExtensionJun 2, 2022
GrantSep 15, 2020
Series BMay 22, 2013
Series A
Apr 23, 2012

Oligomerix, Inc. Investors

Notable investors and investment history

Oligomerix, Inc. investors
InvestorRounds
Wheatley PartnersSeries A
NIH RADxGrant
National Institute on AgingGrant
Alzheimer's Drug Discovery FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 63% MoM, reaching 1.5K.

  • Jan 26, 2026

    Monthly visitors grew 286% MoM, from 235 to 906.

Oligomerix, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oligomerix, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oligomerix, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBronx, New York
Employee Range12
Year Founded2006
Last FundingNov 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?